Peptide Schedule
FOXO4-DRI17 residuesLTLRKEPASEIAQSILEEach bubble = one amino acid. Size = residue mass. Color = chemical class.FOXO4-DRI Dosage Calculator
FOXO4-DRI is a D-retro-inverso peptide engineered to selectively eliminate senescent cells — often called "zombie cells" — that accumulate with age and drive chronic inflammation, tissue deterioration, and age-related disease.
500mcg · 3x/week
Summary: Add 2mL BAC water to your 5mg vial. Draw to 20.0 units on a U-100 syringe for a 500mcg dose. This vial will last 10 doses.
Cycle Planner
FOXO4-DRI Pharmacokinetics
Pharmacokinetics — Active Dose Over Time
t½ = ~2-4 hours (estimated, D-retro-inverso form may extend effective duration)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
FOXO4-DRI Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 500mcg | 3x/week |
| Moderate | 1mg | 3x/week |
| Aggressive | 3mg | EOD |
Note: D-retro-inverso senolytic peptide. Preclinical only — no human trials completed. Extremely expensive due to synthesis complexity. Disrupts FOXO4-p53 interaction in senescent cells. Developed by Peter de Keizer at Erasmus MC. Run in short pulsed cycles with extended off-periods.
About FOXO4-DRI
FOXO4-DRI is a D-retro-inverso peptide engineered to selectively eliminate senescent cells — often called "zombie cells" — that accumulate with age and drive chronic inflammation, tissue deterioration, and age-related disease. It was developed by Peter de Keizer and colleagues at Erasmus University Medical Center in the Netherlands and first described in a 2017 Cell paper. The peptide works by disrupting the interaction between FOXO4 and p53, two proteins that together keep senescent cells alive. When FOXO4-DRI breaks this interaction, p53 is excluded from the nucleus and redirected to the mitochondria, where it triggers apoptosis exclusively in senescent cells while leaving healthy cells unaffected. In preclinical mouse studies, FOXO4-DRI treatment reversed age-related fitness decline, restored fur density, and normalized kidney function markers (plasma urea and creatinine). It also cleared chemotherapy-induced senescent cells. Because FOXO4-DRI uses D-amino acids in a reversed sequence (the retro-inverso approach), it resists protease degradation better than standard L-peptides, giving it improved stability. However, this same property makes it difficult and expensive to synthesize, and no human clinical trials have been completed to date. All dosing information is extrapolated from animal studies and anecdotal protocols — there is no established safe or effective human dose. Researchers continue to study FOXO4-DRI and related senolytic peptides as potential tools for addressing aging at the cellular level, but anyone considering this compound should understand that it remains firmly in the experimental research stage.